CTOs on the Move


 
BIOCiS is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.biocis.org
  • 18 1st St
    Cambridge, MA USA 02141
  • Phone: 617.444.8727

Executives

Name Title Contact Details

Similar Companies

Modis Therapeutics

Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.

Eastern Isotopes

Eastern Isotopes is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ALLERGY ASSOC

ALLERGY ASSOC is a Onalaska, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vanda Pharmaceuticals

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients` lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.